Tango Biosciences, Inc.

Tango Biosciences, Inc. is a Chicago-based biotechnology research company specializing in the development of custom affinity reagents using an innovative phage display platform. Founded in 2016, the firm utilizes protein engineering and combinatorial library screening to generate high-affinity, specific, and reproducible reagents, such as antibodies, antibody mimics, and monobodies. By bypassing traditional animal immunization, Tango’s recombinant workflow provides sustainable tools for challenging targets, enabling applications in research, diagnostics, and therapeutic discovery, including proximity-inducing modalities like molecular glues.

These solutions are critical for partners in the biotech and pharmaceutical industries who require reliable protein detection assays and high-throughput screening capabilities. The company’s technology, which includes its proprietary Avidimer platform, supports the development of targeted protein degradation tools and improved diagnostic assays, such as lateral flow tests for infectious diseases. Through various NIH-funded SBIR programs, Tango Biosciences continues to advance its research in peptide therapeutics and protease profiling, positioning itself as a strategic partner for accelerating early-stage drug discovery and assay development workflows.